Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gemphire Therapeutics Inc    GEMP

GEMPHIRE THERAPEUTICS INC

(GEMP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Gemphire Therapeutics : Shares Fall Over 50% in Heavy Trading -- Market Mover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 12:19pm EDT

Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)

Stocks mentioned in the article
ChangeLast1st jan.
GEMPHIRE THERAPEUTICS INC 6.72% 1.27 Delayed Quote.56.81%
PFIZER -0.31% 42.17 Delayed Quote.-3.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GEMPHIRE THERAPEUTICS INC
03/18GEMPHIRE THERAPEUTICS : Reports Fourth Quarter and Fiscal Year 2018 Financial Re..
AQ
03/18GEMPHIRE THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
03/15GEMPHIRE THERAPEUTICS INC. : Results of Operations and Financial Condition, Fina..
AQ
03/15GEMPHIRE THERAPEUTICS : Reports Fourth Quarter and Fiscal Year 2018 Financial Re..
AQ
03/05GEMPHIRE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K..
AQ
01/31GEMPHIRE THERAPEUTICS INC. : Termination of a Material Definitive Agreement, Tri..
AQ
01/07GEMPHIRE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
2018GEMPHIRE THERAPEUTICS : Announces Review of Strategic Alternatives and Provides ..
AQ
2018GEMPHIRE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
2018GEMPHIRE THERAPEUTICS : Announces Review of Strategic Alternatives and Provides ..
AQ
More news
Financials ($)
Sales 2019 -
EBIT 2019 -57,3 M
Net income 2019 -57,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 0
Capi. / Sales 2020 0
Capitalization 17,0 M
Chart GEMPHIRE THERAPEUTICS INC
Duration : Period :
Gemphire Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GEMPHIRE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,33 $
Spread / Average Target 180%
EPS Revisions
Managers
NameTitle
Steven R. Gullans President, CEO, CFO, CAO & Director
Charles L. Bisgaier Chairman & Chief Scientific Officer
P. Kent Hawryluk Independent Director
Kenneth Kousky Independent Director
Pedro Lichtinger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GEMPHIRE THERAPEUTICS INC56.81%17
GILEAD SCIENCES4.70%83 533
VERTEX PHARMACEUTICALS9.69%46 468
REGENERON PHARMACEUTICALS8.97%43 697
GENMAB4.68%10 456
SAREPTA THERAPEUTICS INC15.89%9 318